Zevra Therapeutics (FRA:1GDA) ROCE % : -58.11% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zevra Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -58.11%.

Zevra Therapeutics ROCE % Historical Data

The historical data trend for Zevra Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics ROCE % Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-185.18

-123.61

-12.33

-23.64

-43.47

Zevra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-53.79	-22.13	-53.15	-52.73	-58.11

Zevra Therapeutics ROCE % Calculation

Zevra Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-40.851	/	( ( (108.881 - 11.35)	+	(158.024 - 67.601) )	/ 2 )
	=	-40.851	/	( (97.531	+	90.423)	/ 2 )
	=	-40.851	/	93.977
	=	-43.47 %

Zevra Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-58.72	/	( ( (158.024 - 67.601)	+	(139.18 - 27.516) )	/ 2 )
	=	-58.72	/	( ( 90.423	+	111.664 )	/ 2 )
	=	-58.72	/	101.0435
	=	-58.11 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Zevra Therapeutics (FRA:1GDA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zevra Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZVRA:USA 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines